Abstract Details

Title Patient and Caregiver Preferences for Acute Seizure Medications: A Quantitative Survey

Topic Epilepsy/Clinical Neurophysiology (EEG)

Presentation(s) P9 - Poster Session 9 (5:00 PM-6:00 PM)

Poster/Presentation
Number 11-003

Objective To explore the preferences of people with epilepsy/an epilepsy syndrome (PwE) and caregivers (CGs) for attributes of acute (on-demand) seizure medications.

Background Rapid and Early Seizure Termination (REST) medications prevent seizures from becoming prolonged/progressing in severity, while rescue medications treat seizures that have already prolonged/progressed.

Design/Methods Survey of PwE aged ≥18 years who had experienced ≥1 prolonged seizure (PS) of ≥2 minutes in the past 12 months and CGs (aged ≥18 years) of PwE aged ≥12 years from France/Italy/Poland/Spain/UK/US. A discrete choice experiment (DCE) was used to elicit treatment preferences (analyzed using multinomial logit models) and a willingness-to-wait exercise for administration of acute seizure medication.

Results

135 adult PwE, 120 CGs of adults, 119 CGs of adolescents participated (N=374): median (Q1-Q3) age 45 (35-54) years, 242 (65%) female. Of 239 CGs, 133 (56%) were parents of PwE. Overall, 173 (46%) participants reported generalized or bilateral/tonic-clonic as their most common seizure type; 193 (52%) reported 3-5 seizures/month on average; and 214 (57%) reported an average duration of 1-4 minutes for the most common seizure type over past 12 months. 212 (57%) participants reported using oral acute medication for PS. In DCE, all attributes significantly influenced treatment preferences (p<0.05); most important was time to seizure cessation (relative attribute importance [RAI]=32.4%) and mode of administration (RAI=26.6%): nasal spray and single-use inhaler were most preferred; rectal was least preferred. Participants preferred treating early in the seizure and faster-acting medications. Willingness-to-wait exercise showed that 328 (88%) participants would be willing to wait 30 seconds (the minimum time proposed) to administer acute seizure medication.

Conclusions Adult PwE and CGs of adult and adolescent PwE value fast-acting acute seizure medications with non-rectal administration (nasal spray and single-use inhaler preferred), and would administer these early in the seizure. Results from the DCE suggest an unmet need with current acute treatments for PS.

Authors/Disclosures
Cedric Laloyaux, PhD (UCBMedical Affairs Center of Expertise) PRESENTER	Dr. Laloyaux has received personal compensation for serving as an employee of UCB.
Tommi Tervonen, PhD	Dr. Tervonen has nothing to disclose.
Vicente Villanueva Haba, MD, PhD	Dr. Villanueva Haba has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Exeltis. Dr. Villanueva Haba has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Villanueva Haba has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Angelini. Dr. Villanueva Haba has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Xenon. Dr. Villanueva Haba has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Rapport. Dr. Villanueva Haba has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. Dr. Villanueva Haba has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Angelini. Dr. Villanueva Haba has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Jazz Pharmaceutical. Dr. Villanueva Haba has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for EISAI. Dr. Villanueva Haba has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for SK. The institution of Dr. Villanueva Haba has received research support from Ministry of Health Spain.
Joseph I. Sirven, MD, FAAN (Mayo Clinic)	Dr. Sirven has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. Dr. Sirven has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurelis. Dr. Sirven has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurona. Dr. Sirven has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN. Dr. Sirven has received publishing royalties from a publication relating to health care. Dr. Sirven has received personal compensation in the range of $10,000-$49,999 for serving as a Host/ Co producer with WJCT Public Media. Dr. Sirven has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant with Federal Aviation Administration .
Alison Kukla (Partners Against Mortality in Epilepsy)	Alison Kukla has received personal compensation for serving as an employee of Epilepsy Foundation of America. Alison Kukla has received personal compensation for serving as an employee of Dartmouth Health. Alison Kukla has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Biosciences Inc. Alison Kukla has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. Alison Kukla has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant with International Bureau for Epilepsy. Alison Kukla has received personal compensation in the range of $50,000-$99,999 for serving as a PAME, Senior Advisor with American Epilepsy Society.
Aura Cecilia Jimenez-Moreno (Evidera)	Aura Cecilia Jimenez-Moreno has nothing to disclose.
Kerrie-Anne Ho (UCB)	Kerrie-Anne Ho has stock in Ucb.

��ɫ��

��ɫ��